Intellectual property is one of the most important assets for a life sciences company. As such, when leading your team members in the buying, selling, licensing, distribution or franchising of IP, the need to engage in a meticulous and strategically timed IP due diligence review is essential to preventing a disappointing or even disastrous outcome.
ACI’s 6th Annual Life Sciences IP Due Diligence Summit is devoted to providing corporate and IP counsel with expert strategies for assessing, valuing and commercializing IP assets when conducting strategic IP due diligence which is essential to nearly every corporate transaction. Our esteemed speakers will provide insights on what to look for during the due diligence process, when to report findings, how to communicate effectively within and across teams, and when to adjust your expectations and decisions as the process proceeds.
2023 CONFERENCE CHAIRS
Tashica Williams Amirgholizadeh, Ph.D.
Senior Associate General Counsel, IP
IP Alliance and Due Diligence (IPADD)
Gilead Sciences, Inc.
Hilary Libka
Chief IP Counsel & Associate General Counsel
Memorial Sloan Kettering Cancer Center
Michael Penn
Vice President, IP
BlueRock Therapeutics
“I am excited to serve as a chair for ACI’s 6th Annual Summit on Life Sciences IP Due Diligence in Boston. Please join us as we hear from an impressive array of panelists providing insightful commentary concerning the state of play in the life sciences sector.”
“Please join us in Boston for ACI’s 6th Annual Summit on Life Sciences IP Due Diligence. From foundational workshops to interactive sessions analyzing recent developments, the Summit will be an enriching experience whether you are new to IP or a seasoned professional. Ask questions and gain unique insights from talented speakers representing the life sciences ecosystem, including pharmaceutical and biotech companies, start-ups, investors, non-profits, government, and private practice.”
“I am honored to co-chair ACI’s 6th Annual Summit on Life Sciences IP Due Diligence here in Boston, where we all have the opportunity to gain valuable insight from a great lineup of panelists well-versed in the field. As we continue to experience challenging capital markets in the pharmaceutical and biotech sectors, join us for a timely discussion related to the interplay of IP with investments, acquisitions and partnering strategies.”
2023 Government Speaker
Hon. Rian Kalden
Presiding Judge, Court of Appeal
Unified Patent Court
2023 Agenda Highlights
- Patents, Price Controls and the IRA: Understanding the Impact of the Inflation Reduction Act on IP Due Diligence Analyses in the Life Sciences Industries
- Protecting Innovation and Unleashing Market Opportunities: Best Practices and Strategic Insights for Validity and Scope Analyses
- Bespoke Due Diligence: Tailoring IP Due Diligence to the Transaction to Achieve the Ideal Balance of Diligence Depth and Cost-Efficiency
- Business Leader’s Roundtable – Unlocking IP Valuation: Retrospective Insights from the Deal-Makers on Working with Outside Counsel and How to Value IP
- Investors Roundtable – Straight from the Horses’ Mouth: Understanding When IP is the Bottom Line for Pharmaceutical and Biotech Investors in Today’s Investment Climate and How to Meet Their Expectations
PRE-CONFERENCE WORKSHOPS
Hone Your Due Diligence Strategies and Expertise by Attending our Workshops
WORKSHOP A
IP Due Diligence 101: The Corporate, Regulatory and Non-Transaction IP Attorney’s Guide to the Fundamentals of Life Sciences IP Due Diligence
Designed as a “101” primer on USC 35 and the IP due diligence checklist to enable deeper understanding of the discussions at the main conference.
November 27, 2023
9:00 am – 12:30 pm
WORKSHOP B
Getting Ahead of IP in the Era of New Modalities and AI: Exploring How Patent Controversies Impact Commercialization Strategies and Global Deal Opportunities
Developed as a deep-dive into the patent strategies, IP due diligence, valuation and commercialization of new therapeutic modalities such as CAR-T, CRISPR, mRNA, and products developed with AI and Machine Learning.
November 27, 2023
1:00 pm – 4:30 pm
SEE WHO ATTENDED IN THE PAST
- AMRI
- Akin Gump Strauss Hauer & Feld LLP
- Allergan plc
- Arnold & Porter Kaye Scholer LLP
- AtriCure Inc
- Axinn Veltrop & Harkrider LLP
- BA Ruskin Law LLC
- BONWRx
- Beck & Thomas
- Biogen
- Blaze Bioscience Inc
- Boehringer Ingelheim GmbH
- Boehringer Ingelheim International GmbH
- Brammer Bio
- Brinks Gilson & Lione
- Cantor Colburn LLP
- Carlson Caspers Vandenburgh Lindquist & Schuman PA
- Centre for Drug Research and Development
- Charles River Associates Inc
- Choate Hall & Stewart LLP
- Cipla Limited
- Clark & Elbing LLP
- Codiak BioSciences
- DRI Capital Inc
- Dentsply Sirona Inc
- Dr. Reddys Laboratories
- Drinker Biddle & Reath LLP
- Duane Morris LLP
- Eisai Inc
- Evolve BioSystems
- Finnegan Henderson Farabow Garrett & Dunner
- Fish & Richardson
- Fitzpatrick Cella Harper & Scinto
- Foghorn Therapeutics
- Forma Therapeutics Inc
- Futuragene
- Genentech Inc
- Gibson Dunn & Crutcher LLP
- Gilead Sciences
- Green Griffith & Borg-Breen LLP
- Heliae
- Hikma Pharmaceuticals USA Inc
- Houlihan Lokey
- Hueschen & Sage PLLC
- Immunogen Inc
- Indivior Inc
- Intellia Therapeutics Inc
- Ipsen Bioscience Inc
- Ironwood Pharmaceuticals Inc
- Jazz Pharmaceuticals
- Johnson-IP Strategy & Policy Consulting
- Jounce Therapeutics Inc
- KSQ Therapeutics Inc
- King & Spalding LLP
- Leason Ellis LLP
- MEDRx
- Marshall Gerstein & Borun LLP
- Mayer Brown LLP
- McDonnell Boehnen Hulbert & Berghoff LLP
- Merchant & Gould
- Merck & Co
- MicroVention Inc.
- Norris McLaughlin & Marcus P.A.
- Novartis
- Novartis Institutes For Biomedical Research
- Novartis Pharmaceuticals
- Obalon Therapeutics
- Ohlandt Greely Ruggiero & Perle LLP
- Paul Hastings LLP
- Pearne & Gordon LLP
- Pepper Hamilton LLP
- Pieris Pharmaceuticals Inc
- Porzio Bromberg & Newman P.C.
- Purdue Pharma LP
- Purdue Research Foundation
- Regeneron Pharmaceuticals Inc
- Roivant Sciences Inc
- Ropes & Gray LLP
- Rutgers Law School
- Sarepta Therapeutics
- Shire Pharmaceuticals
- SmartPharm Therapeutics
- Squire Patton Boggs Us LLP
- Steptoe & Johnson LLP
- Sterne Kessler Goldstein & Fox
- Sun Pharmaceutical Industries Ltd
- Taro Pharmaceutical Industries
- Teva Pharmaceuticals
- Transformative
- US Court of Appeals for Federal Circuit
- University of California
- VBI Vaccines Inc
- VLP Law Group LLP
- Wave Life Sciences
- Wilson Sonsini Goodrich & Rosati PC
Testimonials
Unique high level sessions, good mix of in-house and outside counsel.
Hearing from professionals involved in due diligence on a daily basis was very informative.
Great panels, lots of diversity of practice, and lots of seasoned practitioners.
The design of the event brought us all together along with room intimacy.
